225 related articles for article (PubMed ID: 30608413)
21. Resolving Resistance to Osimertinib Therapy With Afatinib in an NSCLC Patient With EGFR L718Q Mutation.
Yang X; Huang C; Chen R; Zhao J
Clin Lung Cancer; 2020 Jul; 21(4):e258-e260. PubMed ID: 32146032
[No Abstract] [Full Text] [Related]
22. Successful Treatment of a Patient with Lung Adenocarcinoma Harboring Compound EGFR Gene Mutations, G719X and S768I, with Afatinib.
Kutsuzawa N; Takahashi F; Tomomatsu K; Obayashi S; Takeuchi T; Takihara T; Hayama N; Oguma T; Aoki T; Asano K
Tokai J Exp Clin Med; 2020 Sep; 45(3):113-116. PubMed ID: 32901897
[TBL] [Abstract][Full Text] [Related]
23. Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib.
Yamaoka T; Ohba M; Matsunaga Y; Tsurutani J; Ohmori T
J Vis Exp; 2019 Jun; (148):. PubMed ID: 31305510
[TBL] [Abstract][Full Text] [Related]
24. Afatinib treatment in a lung adenocarcinoma patient harboring a rare EGFR L747P mutation.
Li J; Zhu L; Stebbing J; Peng L
J Cancer Res Ther; 2022 Sep; 18(5):1436-1439. PubMed ID: 36204894
[TBL] [Abstract][Full Text] [Related]
25. Long-term response to afatinib in an elderly patient with uncommon epidermal growth factor receptor mutation-positive lung adenocarcinoma.
Shijubou N; Sumi T; Kamada K; Sawai T; Yamada Y; Nakata H; Mori Y; Chiba H
Thorac Cancer; 2021 Mar; 12(6):989-992. PubMed ID: 33533191
[TBL] [Abstract][Full Text] [Related]
26. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.
Yang CJ; Tsai MJ; Hung JY; Lee MH; Tsai YM; Tsai YC; Hsu JF; Liu TC; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 Dec; 18(1):82. PubMed ID: 29237484
[TBL] [Abstract][Full Text] [Related]
27. Successful treatment of an elderly patient with an uncommon L861Q epidermal growth factor receptor mutation with low-dose afatinib: A case report.
Iida Y; Kumasawa F; Shimizu T; Shintani Y; Takahashi N; Gon Y
Thorac Cancer; 2020 Feb; 11(2):447-450. PubMed ID: 31779047
[TBL] [Abstract][Full Text] [Related]
28. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
[TBL] [Abstract][Full Text] [Related]
29. EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib.
Ibrahim U; Saqib A; Atallah JP
Lung Cancer; 2017 Jun; 108():45-47. PubMed ID: 28625646
[TBL] [Abstract][Full Text] [Related]
30. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
[TBL] [Abstract][Full Text] [Related]
31. Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study.
Ho GF; Chai CS; Alip A; Wahid MIA; Abdullah MM; Foo YC; How SH; Zaatar A; Lam KS; Leong KW; Low JS; Yusof MM; Lee EC; Toh YY; Liam CK
BMC Cancer; 2019 Sep; 19(1):896. PubMed ID: 31500587
[TBL] [Abstract][Full Text] [Related]
32. Durable complete response after afatinib and crizotinib in an advanced non-small cell lung cancer patient with EGFR L861Q mutation and acquired MET amplification: a case report.
Long Y; Zhang K; Li Y; Yu M; Zhu J; Huang M
Ann Palliat Med; 2020 Sep; 9(5):3609-3613. PubMed ID: 32648452
[TBL] [Abstract][Full Text] [Related]
33. EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.
He M; Capelletti M; Nafa K; Yun CH; Arcila ME; Miller VA; Ginsberg MS; Zhao B; Kris MG; Eck MJ; Jänne PA; Ladanyi M; Oxnard GR
Clin Cancer Res; 2012 Mar; 18(6):1790-7. PubMed ID: 22190593
[TBL] [Abstract][Full Text] [Related]
34. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study).
Akamatsu H; Koh Y; Okamoto I; Fujimoto D; Bessho A; Azuma K; Morita S; Yamamoto N; Nakagawa K
Lung Cancer; 2019 May; 131():128-133. PubMed ID: 31027689
[TBL] [Abstract][Full Text] [Related]
36. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
[TBL] [Abstract][Full Text] [Related]
37. Afatinib as first-line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature.
Shi Y; Wang M
Thorac Cancer; 2018 Dec; 9(12):1788-1794. PubMed ID: 30379401
[TBL] [Abstract][Full Text] [Related]
38. A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).
Yokoyama T; Yoshioka H; Fujimoto D; Demura Y; Hirano K; Kawai T; Kagami R; Washio Y; Ishida T; Kogo M; Tomii K; Okuno T; Akai M; Hirabayashi M; Nishimura T; Nakahara Y; Kim YH; Miyakoshi C; Yoshimura K; Hirai T;
Lung Cancer; 2019 Sep; 135():175-180. PubMed ID: 31446992
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy of first-line afatinib versus chemotherapy in EGFR mutation positive pulmonary adenocarcinoma].
Sárosi V; Balikó Z
Magy Onkol; 2014 Dec; 58(4):325-9. PubMed ID: 25517450
[TBL] [Abstract][Full Text] [Related]
40. Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors.
Qin Y; Jian H; Tong X; Wu X; Wang F; Shao YW; Zhao X
Mol Oncol; 2020 Aug; 14(8):1695-1704. PubMed ID: 32412152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
